Tag: Interleukin 17a

Developed by the Swiss pharmaceutical company Novartis, the groundbreaking biologic Cosentyx, or **secukinumab**, was the first interleukin-17A (IL-17A) inhibitor to receive FDA approval, marking a significant advancement for treating autoimmune and inflammatory diseases. Its development was a long process involving extensive research into inflammatory pathways.

First approved by the FDA in 2016 for moderate-to-severe plaque psoriasis, the Taltz autoinjector is a biologic medication that delivers ixekizumab to treat several inflammatory autoimmune conditions. This targeted therapy is designed to interrupt the specific immune pathways that cause inflammation, providing symptom relief for eligible patients.